New combo therapy targets tough pancreatic cancer

NCT ID NCT05257993

Recruiting now Disease control Sponsor: Onconic Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Apr 16, 2026 · Last updated May 22, 2026 · Updated 4 times

Summary

This study is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It tests a new drug called JPI-547 given together with standard chemotherapy. The goal is to find the best dose and see if the combination is safe and helps shrink or control the cancer. About 71 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Samsung Medical Center
RECRUITING

Seoul, South Korea

Contact
Seoul National University Bundang Hospital
RECRUITING

Gyeonggi-do, South Korea

Contact
Seoul national university hospital
RECRUITING

Seoul, South Korea

Contact
Severance Hospital
RECRUITING

Seoul, South Korea

Contact

Conditions

Explore the condition pages connected to this study.

PANCREATIC DUCTAL ADENOCARCINOMA PANCREATIC DUCTAL ADENOCARCINOMA